{"entity":{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","aka":[],"tldr":"A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., now recruiting.","summary":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec is a phase 2 interventional study registered as NCT07332000 by Candel Therapeutics, Inc., with 45 participants planned, started 2025-10-30 and due to reach its primary completion in 2027-02. Interventions recorded: aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT). Conditions listed: Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07332000","url":"https://clinicaltrials.gov/study/NCT07332000"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":["candel-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07332000","phase":"2","setting":"A Biomarker Study in Men With Localized, Favorable, Intermediate-risk Prostate Cancer Treated With Aglatimagene Besadenovec","sponsor":"Candel Therapeutics, Inc.","enrolled":45,"outcomes":[]},"route":"/trials/nct07332000/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/"}],"company":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"}]}}